Jasper Therapeutics is trading 5.3% down at $0.60 in pre-market after reversing part of the September 17 regular-session gain.
- No clear company-specific announcement or late-breaking catalyst was identified for the September 18 pre-market decline.
- Recent coverage involved executive appointments and an H.C. Wainwright conference discussion, but neither directly explains the move.
- Broader markets are mixed, so the decline cannot be confidently attributed to overall sentiment.